ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

T. Oh, Stephen; Talpaz, Moshe; T. Gerds, Aaron; Gupta, Vikas; Verstovšek, Srđan; A. Mesa, Ruben; B. Miller, Carole; E. Rivera, Candido; G. Fleischman, Angela; Goel, Swati; Heaney, Mark; L. O’Connell, Casey; O. Arcasoy, Murat; Zhang, Yafeng; Kawashima, Jun; Ganz, Tomas; Kowalski, Mark; Baker Brachmann, Carrie

doi:10.1182/bloodadvances.2020002662

Public

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Published in Blood Advances • Sep 11, 2020

Authors:

Stephen T. Oh

Moshe Talpaz

Aaron T. Gerds

Abstract

Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly. In this phase 2 open-label translational biology study (NCT02515630) of 41 transfusion-dependent patients with MF, we exp...

Subject

Hepcidin

Anemia

Myelofibrosis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!